Which antibiotic is commonly used for IV treatment of MRSA?

Vancomycin is a glycopeptide antibiotic that is commonly used as a first-line treatment for infections caused by methicillin-resistant Staphylococcus aureus (MRSA). The antibiotic works by inhibiting cell wall synthesis, which is crucial for bacterial growth and survival. MRSA is known for its resistance to many commonly used antibiotics, including methicillin, which is why effective treatment options are necessary.

Vancomycin is administered intravenously (IV) when treating serious MRSA infections, particularly in settings such as hospitals where the severity of the infection can warrant more aggressive treatment. Its effectiveness against MRSA and its ability to reach adequate concentrations in the bloodstream make it a critical choice for such cases.

In contrast, other options provided have different indications or are generally not effective against MRSA. For example, azithromycin and ciprofloxacin do not have reliable efficacy against MRSA, while clindamycin, although sometimes effective in certain cases, is not considered the first-line treatment for severe MRSA infections when an IV option is needed.